Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02667418 · ClinicalTrials.gov registry record · Phase 4
Optimal Treatment for Recurrent Clostridium Difficile
A Phase 4 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 4
- Development phase
- 308
- Enrollment target
NCT02667418: Clinical Trial Phase 4 study, sponsored by VA Office of Research and Development.
NCT02667418 is a Phase 4 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 308 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02667418, a Phase 4 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 308 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether fidaxomicin and vancomycin followed by taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the treatment of recurrent Clostridium difficile infection.
Interventions
- DRUG Vancomycin
- DRUG Fidaxomicin
- DRUG Vancomycin with Taper/Pulse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2016-02-19 |
| Est. Completion | 2024-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02667418
The ClinicalTrials.gov registry entry for NCT02667418 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vancomycin is the first listed.
NCT02667418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02667418 about?
NCT02667418 is a clinical study titled "Optimal Treatment for Recurrent Clostridium Difficile". The purpose of this study is to determine whether fidaxomicin and vancomycin followed by taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the treatment of recurrent Clostridium difficile infection.
What is the current status of trial NCT02667418?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 308 participants. The study started on 2016-02-19. Estimated completion is 2024-08-31.
What interventions are being tested in trial NCT02667418?
The interventions under investigation include: Vancomycin (DRUG), Fidaxomicin (DRUG), Vancomycin with Taper/Pulse (DRUG).
Who is sponsoring clinical trial NCT02667418?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.